Introduction {#sec1-1}
============

Non-atopic dermatitis (NAD) or eczema is a common inflammatory condition; potentially debilitating that can compromise quality of life. It is usually seen in childhood, but can onset within or persist into adulthood.^[@ref1]^ Diagnosis of NAD is based on the findings of the history and physical examination; exposure to possible exacerbating factors, such as aeroallergens, irritating chemicals, foods and emotional stress, should be investigated.^[@ref2]^

Unfortunately, no specific laboratory findings or histologic features define NAD. Although elevated IgE levels are found in up to 80 percent of affected patients, but IgE levels are also elevated in patients with other non-atopic diseases.^[@ref3]^ Pruritus is a universal finding in NAD. The pruritus can be severe, sometimes causing sleep disruption, irritability and generalized stress for affected patients and family members. Pruritus leads to scratching that can result in secondary skin changes such as lichenification (thick accentuation of skin lines), excoriation and abrasions with breakdown of the skin barrier. Consequently, NAD has been referred to as *the itch that rashes* rather than the *rash that itches*.^[@ref4]^ Xerosis (dry skin) is another characteristic skin finding in patients with NAD. Because xerotic skin is unable to hold moisture, it is less pliable and more likely to crack and fissure. Resultant skin barrier breakdown increases susceptibility to irritation and infection. Reversing xerosis is one of the key elements and goals in the treatment of NAD.^[@ref5]^ Based on the presenting characteristics, it is possible to categorize levels of severity. For example, a moderate condition is characterized by areas of dry skin, frequent itching, erythema and a moderate impact on everyday activities and psychosocial wellbeing.^[@ref6]^ The treatment of NAD targets underlying skin abnormalities such as xerosis, pruritus, superinfection and inflammation. Patients should also be educated about the chronic nature of the disease and the need for continued adherence to proper skin care. The first line of treatment is based on topical emollients, calcineurin inhibitors, corticoids followed by systemic immunomodulation drugs and ultraviolet (UV) phototherapy as appropriate for the severity of the condition.^[@ref7]^

Light therapy including low level laser as a coherent source of light and polarized UV-free polychromatic no coherent light therapy (*e.g*., Bioptron light therapy systems, Bioptron, Switzerland) have been proposed as nonaggressive, safe and cost effective therapeutic option for the treatment of several musculoskeletal disorders and skin conditions.^[@ref8]^ The Bioptron light therapy system is a device with an optical unit emitting light that is similar to a part of the electromagnetic spectrum produced by the sun but with no UV radiation, reducing the potential side effects to no more than transient redness.^[@ref9]^ The light emitted by Bioptron light therapy system can be characterized as polarized (its waves oscillate on parallel planes), polychromatic (wavelength: 480-3400 nm), incoherent (out of phase light, unlike laser light) and low energy light.^[@ref10]^ These different wavelengths (480-3400 nm) of Bioptron light therapy devices penetrate the skin at different depths triggering and enhancing a variety of cellular processes with beneficial physiological effects;^[@ref13],[@ref14]^ including resolution of inflammation and activation of the immune system,^[@ref15]^ mitochondria activation,^[@ref19]^ reduction of pain intensity,^[@ref20]^ wound healing and tissue repair^[@ref23]^ vasodilatation and increased local and systemic circulation.^[@ref30],[@ref31]^

Bioptron light has so-called bio-stimulative effects: when applied to the skin, it stimulates generation of collagen, elastin among others light-sensitive intracellular biomolecules.^[@ref32]^ This initiates cellular chain reactions and also triggers secondary responses not only limited to the treated skin area but can affect the whole body.^[@ref9]^

The efficacy of light therapy including low level laser and polarized light on NAD has not been adequately investigated. There are studies evaluating the effect of classic phototherapy showing important side effects derived from the amount of UVAUVB content,^[@ref33]^ and there are a few unpublished observations on the effectiveness of polarized light (Bioptron) in atopic dermatitis in predominantly children. In 3 unpublished case report studies documented in Eastern Europe, where 198 patients were treated daily with the Bioptron device for atopic dermatitis.^[@ref34]^ Particularly in children with NAD, erythema, itching, cracks and excoriations due to scratching were decreased or eliminated. The authors of these unpublished reports conclude a good therapeutic effect for NAD and attributed the analgesic, anti-inflammatory, anti-pruritus and trophostimulating effects to the Bioptron irradiation device. Improved skin elasticity by the 5th treatment was also noted, and after 1 week of treatment with the Bioptron device lead to a disappearance of symptoms of lichenification. Furthermore, the Federal Educational Agency/Russian People's Friendship University has edited an exactly elaborated and very detailed guideline for physicians indicating the correct use of the Bioptron light therapy system in dermatological indications. ^[@ref35]^ Moreover, the Ministry of Public Health and Social Development of the Russian Federation has prepared a Manual for Physicians^[@ref36],[@ref37]^ using polychromatic incoherent polarized light for several dermatological, cosmetically and aesthetic-surgical indications. Yet, the clinical efficacy of polarized light was never published in a peer-reviewed journal. A previous study using a similar device, showed beneficial effects on 70 patients,^[@ref24]^ however the results are not conclusive nor accessible for the medical community at large. Therefore, we sought to investigate the clinical efficacy of polarized polychromatic noncoherent Light (Bioptron) therapy in NAD with particular focus on itchiness, dryness and size of lesion areas.

Case Report {#sec1-2}
===========

A 67-year-old Caucasian female patient presented with an intermittent moderate presentation of NAD for the last 20 years and had visited multiple specialists and had undergone several treatments in the last decade, which all proved ineffective for managing her condition. Three months before the first private consultation, she presented with signs of NAD on the palmar surface of the hands and the popliteal fossa. Firstly, she self-treated the areas with contact use of emollients based on Bepanthol (an over the counter ointment). After 2 weeks of no improvement she consulted with a specialist and commenced topical steroid therapy with Mometasone 0.1% ointment every day for 1 week. As there was no improvement and an increase in dryness, the therapeutic strategy was changed to Betamethasone 0.1% every day for 1 week. Additionally, levocetirizine dihydrochloride (levocetirizine) (5 mg/day) antihistamine was added. No oral corticoids were used as previous medical history showed that the patient responded negatively to Prednisone 10 mg, presenting with a hypertensive crisis. Additionally, a skin allergy test (prick test) was performed and negative for the standard panel of allergens. The itchiness, redness and dryness failed to resolve and the patient decided to suspend treatments.

Furthermore, the patient's medical history was positive for controlled hypertension (treated with losartan 50 mg/twice daily, nebivolol 5 mg/day, amlodipine 5 mg daily) and Hashimoto's hypothyroidism (treated with 100 mcg levothyroxine daily).

Demographic characteristics at the start of treatment are summarized in [Table 1](#table001){ref-type="table"}.

![Progression of the areas with non-atopic dermatitis in the knee pit before, during and after the treatment with light therapy.](cp-9-3-1161-g001){#fig001}

Polarized UV-free polychromatic light treatment {#sec2-1}
-----------------------------------------------

A Bioptron light therapy phototherapeutic device (Bioptron AG, Wollerau, Switzerland) with 5 cm treatment diameter (BIOPTRON MedAll®, 480-3400 nm, polarization level of 95%, power density 40 mW/cm^2^, energy density 2,4 J/cm^2^ per minute) was used for irradiation of the affected area of the skin. Polarized light therapy was administrated daily for six weeks in a domiciliary care setting. Bioptron was placed at 90° to the surface and at a 10-cm distance from the cleaned skin area, for 10 minutes per section. The total treatment per day consisted of irradiation of five areas (total irradiation of 50 minutes). No emollient was used before and after the light exposure. One follow-up appointment was made 1 week after the completion of the 6-week treatment. The subject gave her informed consent for inclusion before she participated in the study. The study was conducted in accordance with the Declaration of Helsinki.

Outcome measures {#sec2-2}
----------------

Photo-documentation of the affected areas were assessed prior to treatment and on a weekly basis thereafter for a total of 7 weeks (6 weeks of treatment and 1 week of follow up after the therapy was completed). In addition, erythema, pruritus and dryness of skin were quantified on a weekly basis. Erythema (redness) and size of the skin area affected were quantified with by ImageJ (National Institutes of Health) according to standard procedures. Pruritus was assessed using a survey based 5-D itch scale.^[@ref38]^ Dryness of the skin was assessed according to a previously observational and selfassessment published scale.^[@ref39]^

###### 

Clinical, demographic, biochemical and anthropometric characteristics.

  --------------------------------- ------------
  Weight (Kg)                       67
  BMI (Kg/m2)                       29
  Basal glucose (mg/dL)             79
  Basal triglycerides (mg/dL)       110
  Basal total cholesterol (mg/dL)   164
      HDL                           58
      LDL                           84
  Systolic blood pressure (mmHg)    125
  Diastolic blood pressure (mmHg)   68
  Itch scale (0-25)                 16.8
  Dryness scale (1-4)               3 (severe)
  Social habits                     
      Alcohol use                   No
      Smoking                       No
  --------------------------------- ------------

BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

Follow-up {#sec2-3}
---------

In general, the patient reported a significant improvement in comfort with immediate resolution and relief from pruritic symptoms and erythema with the commencement of polarized light therapy. As shown in [Figure 1](#fig001){ref-type="fig"}, the patient initially presented with pruritus, active vesicles, redness and dryness in the popliteal fossa.

After the 1st week after commencing treatment an increase in redness was observed but it quickly improved from the 4th week to the end of the treatment. The quantification of the area and intensity confirmed the observations ([Figure 2](#fig002){ref-type="fig"}). Interestingly, at the 3rd week the patient presented an active lesion described by herself as a product of the use of tight trousers. This information suggests that the lesion was caused by friction and it resolved in seven days.

In the hands palms and wrist, the patient presented with small active breakable lesions ([Figure 3](#fig003){ref-type="fig"}) that showed a sustained reduction in redness and area with treatment of polarized light that starting from the 2nd week onwards ([Figure 4](#fig004){ref-type="fig"}).

Using the 5-D Itch Scale,^[@ref40]^ light therapy reduces the itchiness starting from the 1st week, an effect that was sustained during and after the treatment ([Figure 5A](#fig005){ref-type="fig"}). Additionally, the polarized light improved the overall dryness of the skin ([Figure 5B](#fig005){ref-type="fig"}).

One week after completion of the 6- week therapy with polarized light, in the popliteal fossa there was a slight increase in redness and active vesicles, accompanied with a self-report of mild itchiness. In the hands, palms and wrist, however, no changes were observed after 1 week after therapy (without light therapy treatment). The overall dryness of the skin was slightlynegatively affected after one week without the treatment.

Discussion {#sec1-3}
==========

The aim of this case study was to evaluate the effectiveness of polarized, UV-free, polychromatic light therapy in a patient with chronic NAD. This trial demonstrated an important improvement in our patient's symptoms (erythema, pruritus and area size) and presentation of chronic NAD with Bioptron light therapy treatment, and reported welcomed comfort and relief from symptoms with less interference in her daily activities.

![Semi quantification of (A) area and (B) redness intensity in knee pit non-atopic dermatitis sections before, during and after the treatment with light therapy.](cp-9-3-1161-g002){#fig002}

In this study, 6 weeks of Bioptron light therapy reduced erythema and lesion size in the hands and popliteal fossa. However, in the popliteal fossa, we observed an initial increase on redness and its size with treatment, but this was not associated with active vesicles or flakes, and moreover resolved after the 3rd week of light therapy treatment. In general, a significant reduction in itchiness and dryness was observed, increasing the patients comfort and overall adherence to the non-pharmacological treatment.

In this particular case the patient presented following a series of unsuccessful treatments in the last 20 years that caused her frustration in regards to the condition. For that reason, it is pivotal to study new adjunctive therapies and implement measurements to increase the adherence to treatment regimens.^[@ref40],[@ref41]^ Current treatments, particularly topic corticoids are associated with a poor adherence and compliance^[@ref42]^ affecting long term effectiveness and control of the chronic condition.^[@ref43]^ Here, we report on a non-pharmaceutical and safe treatment method that was well tolerated by this patient.

Interestingly, the interruption of the treatment seems to reverse the benefits observed suggesting that polarized light would be required as an ongoing treatment alongside an established daily or weekly regimen. Polarized, UV-free, polychromatic light could be considered in cases of mild NAD with limited and not extensive lesion areas when other interventions are not successful, associated with poor compliance or have failed to resolve symptoms for the patient.

Even when polarized, UV-free, polychromatic light has been tested for various conditions, such as cutaneous and mucosal ulcerative lesions,^[@ref8]^ pressure ulcer healing,^[@ref44]^ acne vulgaris management,^[@ref45]^ diabetic foot complicated by atherosclerosis^[@ref46]^ and purulent- septic surgery,^[@ref47]^ more research is needed to understand its effect on NAD and other dermatological conditions. More clinical studies are needed to understand the therapeutic properties of polarized, UVfree, polychromatic light and to acknowledge its benefits, even though our findings suggest encouraging possibilities for the use of this therapy as a management strategy for recurrent moderate NAD.

![Progression of the areas with non-atopic dermatitis in the hands before, during and after the treatment with light therapy.](cp-9-3-1161-g003){#fig003}

![Semi quantification of (A) area and (B) redness intensity in hands non-atopic dermatitis sections before, during and after the treatment with light therapy.](cp-9-3-1161-g004){#fig004}

![Overall quantification of (A) itchiness and (B) dryness based on weekly evaluations.](cp-9-3-1161-g005){#fig005}

Conclusions {#sec1-4}
===========

Our results suggest that polarized UVfree polychromatic light therapy may offer an effective treatment option for chronic NAD that is well tolerated and free of side effects.

The authors are grateful to the patient for her cooperation in preparing this case report.
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